1. Growing interest
1.1. It came after
1.1.1. Strict regulations about psychedelic and hallucinogen stand down
1.1.1.1. it made appear
1.1.1.1.1. Research about the use of psychedelic and hallucinogen as a possible variant of therapy
1.1.1.1.2. People, professionals and scientific attenction for PAT (psychedelic-assisted therapy)
2. Lack of knowledge
2.1. Psilocybin and MDMA as therapies for depression, anxiety an PTSD have ben recent advancements in treating these disorders
2.1.1. However
2.1.1.1. since they´re psychoactive substances, there aren´t enough studies to confirm their effectiveness
2.1.1.1.1. for this reason
2.1.1.2. This lack of knowledge is also evident among healthcare professionals
2.1.1.2.1. Who in surveys
3. Difference in perception
3.1. Both, psilocybin and MDMA are psychedelic, but for professionals, when talking about PAT these are not the same
3.1.1. Proffesionals think...
3.1.1.1. Psilocybin is more favorable for therapy
3.1.1.1.1. and they are more open to
3.1.1.2. MDMA is associated with higher risks
3.1.1.2.1. FDA appeal for more trials to find how viable can be MDMA for PAT
4. Demographics
4.1. Perceptions are our POV (point of view) of the world
4.1.1. Perceptions about PAT can change between every professional
4.1.1.1. Because of
4.1.1.1.1. Age
4.1.1.1.2. Gender
4.1.1.1.3. Race and culture
4.1.1.1.4. Profession
4.1.1.1.5. Personal experience
5. Legal access
5.1. Professionals belive
5.1.1. That
5.1.1.1. The legal access to psilocybin and MDMA should be supported for medical use
5.1.1.1.1. With psilocybin receiving the highest percentage of support
5.1.1.2. The legal recreational access to psilocybin and MDMA should not be supported.
5.1.1.2.1. However
6. Concerns about PAT implementation
6.1. There are some thing to have in mind when talking about PAT
6.1.1. Such as
6.1.1.1. Financial costs
6.1.1.1.1. As others therapies, it can go wrong
6.1.1.2. Time Needed
6.1.1.2.1. Professional concern about the amount of time needed for therapy with psilocybin and MDMA
6.1.1.3. Ethical considerations and risks
6.1.1.3.1. PAT its risky because...
7. The providers
7.1. Among the highest rated concerns
7.1.1. Is the
7.1.1.1. Lack of trained providers
7.1.1.1.1. This is important because without them and without sufficient trained personnel, patients could experiences different side effects, and without the adequate support
7.1.1.2. Consequences and Risks
7.1.1.2.1. The lack of quealified staff
7.1.1.2.2. Only the professionals can assess the risks that future patients might face.